Nome Bio uses AI to map treatment paths for ultra-rare diseases

A startup founded by a patient with a rare genetic disorder is building an AI-powered service to help families navigate the complex journey from diagnosis to treatment development for ultra-rare diseases.

Nome Bio targets patient groups often overlooked by traditional pharmaceutical companies—those with genetic conditions affecting fewer than 200 people worldwide. The company provides both initial treatment assessments and full project management for clinical development, aiming to reduce costs and timelines for personalized therapies.

From diagnosis to desperation

Jacalyn Lee's experience illustrates the gap Nome seeks to fill. When her daughter Isla was diagnosed at age three with DEAF1-Associated Neurodevelopmental Disorder (DAND)—a condition affecting roughly 200 patients globally—Lee and four other mothers formed The DAND Alliance to fund treatment research.

But the working mothers struggled to navigate the technical complexity of drug development while managing their families and careers. "We were handed this diagnosis, and little else," Lee said. "There was no roadmap, barely any research, no community."

The group needed help determining where to allocate limited funds and how to sequence the steps from animal studies to trial design. They turned to Nome for a comprehensive development plan.

AI-powered treatment mapping

Nome's core technology analyzes genetic test results to identify potential treatment options in approximately 10 minutes, with PhD review before delivery to patients. The company has processed roughly 5,000 cases to date, identifying viable programmable medicine or custom therapy options in about 25% of cases.

The service begins with free detailed reports. Nome generates revenue when families hire the company to design clinical trials or manage the full development process through patient dosing. The startup currently oversees more than 10 genetic medicine programs and produces 80 to 100 initial assessments monthly.

Founder and CEO Stevie Ringel developed the concept after his own experience with a rare inherited eye disorder caused by KIZ gene mutation. He launched the Kizuna Foundation to fund treatment development but found the process uncertain and resource-intensive.

Automation to reduce costs

Nome currently automates approximately 25% of its work using AI systems. Ringel projects that figure could reach 60-80% within one to two years as the company's models advance.

In personalized medicine, where human capital drives much of the cost, this automation matters. Ringel noted that customized antisense oligonucleotide (ASO) therapies currently cost between $1.2 million and $1.4 million. A 50% cost reduction could create a pathway for insurance coverage, similar to how CAR-T cancer therapies transitioned from being considered too expensive to now receiving coverage from most public and private plans.

For scientific expertise, Nome partners with more than 80 organizations including La Jolla Labs and Dyno Therapeutics. Ringel positions the company as a logistics operation connecting established science to patients who need it.

Why it matters

Thousands of rare genetic diseases lack treatment options because patient populations are too small to attract traditional pharmaceutical investment. AI-driven automation could fundamentally change the economics of personalized medicine development, potentially making individualized therapies accessible to patient groups that currently have no path forward. If Nome's model proves viable at scale, it could establish a new category of drug development infrastructure specifically designed for ultra-rare conditions.

For The DAND Alliance, Nome delivered a 53-page roadmap detailing next steps, potential researchers, and vendors—all within a timeframe and budget that surprised Lee. "It can give you options," she said of the service's value during an isolating time following diagnosis.

These details were first reported by CNBC.